Safety and Durability of Sirolimus for Treatment of LAM
Safety and Durability of Sirolimus for Treatment of LAM
Recruiting · NCT02432560 · Registry updated 2024-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Durability of Sirolimus for Treatment of LAM | Hemic and Lymphatic Diseases, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, immune system disorder, immunoproliferative disorder, lymphangioleiomyomatosis, lymphangiomyoma, lymphatic system disorder, lymphoproliferative syndrome, neoplasm, neoplasm with perivascular epithelioid cell differentiation | Recruiting | Not stated | 2024-12-24 | NCT02432560 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
20 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.